# Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?

> **NCT06742333** · PHASE2 · RECRUITING · sponsor: **Centre Hospitalier Universitaire de Nice** · enrollment: 40 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Bimekizumab
- **DRUG:** Clobetasol

## Key facts

- **NCT ID:** NCT06742333
- **Lead sponsor:** Centre Hospitalier Universitaire de Nice
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-22
- **Primary completion:** 2028-07-22
- **Final completion:** 2029-01-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06742333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06742333, "Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06742333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*